An internal standard for the quantification of Nε-(1-carboxymethyl)-L-lysine
Related Products
Unlabeled Version(s)
16483Nε-(1-Carboxymethyl)-L-lysine
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Nε-(1-Carboxymethyl)-L-lysine-d3

Item No. 26785

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N6-(carboxymethyl)-L-lysine-2,6,6-d3
CAS Number
2699607-49-1
Synonyms
  • CML-d3
Molecular Formula
C8H13D3N2O4
Formula Weight
207.2
Purity
≥99% deuterated forms (d1-d3)
Formulation
A solid
Solubility(Learn about Variance in Solubility)
PBS (pH 7.2): 10 mg/ml
SMILES
OC(CNC([2H])([2H])CCC[C@@](N)([2H])C(O)=O)=O
InChi Code
InChI=1S/C8H16N2O4/c9-6(8(13)14)3-1-2-4-10-5-7(11)12/h6,10H,1-5,9H2,(H,11,12)(H,13,14)/t6-/m0/s1/i4D2,6D
InChi Key
NUXSIDPKKIEIMI-SASOZDAZSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $215

    Add

    1 mg

    $366

    Add

    5 mg

    $1,395

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Nε-(1-Carboxymethyl)-L-lysine-d3 (CML-d3) is intended for use as an internal standard for the quantification of CML (Item No. 16483) by GC- or LC-MS. CML is an advanced glycation end product (AGE), produced by the oxidative modification of glycated proteins during oxidative stress.1,2,3 Levels of CML increase with aging and during diabetes, cancer, vascular disease, and other pathologies marked by oxidative stress.1,4,5 CML activates the membrane-bound receptor for AGEs (RAGE), triggering signaling through MAPKs and NF-κB, whereas truncation of RAGE produces a soluble protein that binds CML and reduces signaling.6,7

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Requena, J.R., Ahemd, M.U., Fountain, C.W., et al. Carboxymethylethanolamine, a biomarker of phospholipid modification during the maillard reaction in vivo. The Journal of Biological Chemisty 272(28), 17473-17479 (1997).

    2. Ahmed, M.U., Brinkmann, F.E., Degenhardt, T.P., et al. Nε-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem. J. 324(Pt 2), 565-570 (1997).

    3. Schleicher, E.D., Wagner, E., and Nerlich, A.G. Increased accumulation of the glycoxidation product Nε-(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest. 99(3), 457-468 (1997).

    4. Campbell, D.J., Somaratne, J.B., Jenkins, A.J., et al. Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. Cardiovasc. Diabetol. 10, 1-14 (2011).

    5. Brouwers, O., de Vos-Houben, J.M.J., Niessen, P.M.G., et al. Mild oxidative damage in the diabetic rat heart is attenuated by glyoxalase-1 overexpression. Int. J. Mol. Sci. 14(8), 15724-15739 (2013).

    6. Schmidt, A.M., Yan, S.D., Yan, S.F., et al. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta 1498(2-3), 99-111 (2000).

    7. Moy, K.A., Jiao, L., Freedman, N.D., et al. Soluble receptor for advanced glycation end products and risk of liver cancer. Hepatology 57(6), 2338-2345 (2013).